FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2785465551> ?p ?o ?g. }

• W2785465551 endingPage "B132" @default.
• W2785465551 startingPage "B132" @default.
• W2785465551 abstract "Abstract Introduction: As the prognosis of metastatic gastric cancer patients is extremely poor, development of novel effective treatment is necessary. Pexa-Vec (pexastimogene devacirpvec; JX-594) engineered from the Wyeth vaccine strain has emerged as an attractive oncolytic virotherapy in cancer treatment. The aim of this study is to investigate the efficacy of Pexa-Vec against human gastric cancer cell lines and to identify potential biomarkers of oncolytic virotherapy. Method: Forty-nine human gastric cancer cell lines and normal human umbilical vein endothelial cell (HUVEC), FHs 173We, human embryonic kindey 293(HEK 293), and Hela cell line as control were used in this study. For evaluation of cytopathic effect, gastric cancer cells were infected with JX594 (M.O.I [multiplicity of infection]= 0.1-5), then incubated at 37°C. Cell viability was measured 72 hours postinfection using MTT assay. Viral plaque assay was used for quantification of Pexa-Vec infection. Copy number variation (CNV), single nucleotide variation (SNV), gene expression using whole exome sequencing (WES,) and RNA sequencing of 49 gastric cancer cell lines were analyzed. In addition, expression levels for TK and EGFR family were confirmed by Western blot, and secreted VEGF (vascular endothelial growth factor) levels in conditioned media of gastric cancer were measured using ELISA (enzyme-linked immunosorbent assay). Result: Cytopathic effect of Pexa-Vec was observed in all 49 gastric cancer cell lines. Median ED 50 (effective dose 50) was 0.37 pfu/cell (range 0.02-6.18) in gastric cancer cells and 0.30 pfu/cell (range 0.14-1.67) in normal control cells. Interestingly, EBV-infected cells (YCCEL1/YCC-10, SNU 719) showed relative resistance to Pexa-Vec when compared with other cells (ED 50; 4.34 [range 2.49-6.18]) vs 0.36 pfu/cell (range 0.02-5.00, p=0.003). Plaque assay was performed to quantify Pexa-Vec viral infection of gastric cancer cell lines, but the plaques were too small and diffuse to quantify. Increase in virus M.O.I. seemed to be correlated with increase in plaque numbers, yet this did not explain the association with the degree of TK expression in gastric cancer cells. In addition, EGFR, HER2, HER3, and secreted VEGF expressions were not related to the cytotoxicity of Pexa-Vec (R=-0.19, p=0.19; R=0.06, p=0.537; R=0.18, p=0.232; R=-0.067, p=0.69). From RNA sequencing data, VEGF B expression showed negative correlation with antitumor acitivity of Pexa-Vec (R=- 0.295, p=0.04). Conclusion: Pexa-Vec showed moderate antitumor effects in gastric cancer cell lines in vitro compared with other cancer types. Interestingly, EBV-infected gastric cancer cells showed relatively lower efficacy. In our study, correlation was not observed between TK and EGFR expression levels and cytopathic effects. Therefore, we need to further investigate the mechanisms of action of Pexa-Vec for development of metastatic gastric cancer treatment. Citation Format: Jee Hung Kim, Woo Sun Kwon, Tae Soo Kim, Kyu Hyun Park, Joong Bae Ahn, Namhee Lee, Ji Won Choi, Hyun Cheol Chung, Sun Young Rha. Antitumor effect of oncolytic vaccinia virus in gastric cancer [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B132." @default.
• W2785465551 created "2018-02-23" @default.
• W2785465551 creator A5018583230 @default.
• W2785465551 creator A5018855696 @default.
• W2785465551 creator A5024676627 @default.
• W2785465551 creator A5028794004 @default.
• W2785465551 creator A5038994402 @default.
• W2785465551 creator A5046218009 @default.
• W2785465551 creator A5064404544 @default.
• W2785465551 creator A5067172804 @default.
• W2785465551 creator A5090832721 @default.
• W2785465551 date "2018-01-01" @default.
• W2785465551 modified "2023-09-27" @default.
• W2785465551 title "Abstract B132: Antitumor effect of oncolytic vaccinia virus in gastric cancer" @default.
• W2785465551 doi "https://doi.org/10.1158/1535-7163.targ-17-b132" @default.
• W2785465551 hasPublicationYear "2018" @default.
• W2785465551 type Work @default.
• W2785465551 sameAs 2785465551 @default.
• W2785465551 citedByCount "0" @default.
• W2785465551 crossrefType "journal-article" @default.
• W2785465551 hasAuthorship W2785465551A5018583230 @default.
• W2785465551 hasAuthorship W2785465551A5018855696 @default.
• W2785465551 hasAuthorship W2785465551A5024676627 @default.
• W2785465551 hasAuthorship W2785465551A5028794004 @default.
• W2785465551 hasAuthorship W2785465551A5038994402 @default.
• W2785465551 hasAuthorship W2785465551A5046218009 @default.
• W2785465551 hasAuthorship W2785465551A5064404544 @default.
• W2785465551 hasAuthorship W2785465551A5067172804 @default.
• W2785465551 hasAuthorship W2785465551A5090832721 @default.
• W2785465551 hasConcept C121608353 @default.
• W2785465551 hasConcept C153911025 @default.
• W2785465551 hasConcept C159047783 @default.
• W2785465551 hasConcept C203233990 @default.
• W2785465551 hasConcept C2522874641 @default.
• W2785465551 hasConcept C2777283488 @default.
• W2785465551 hasConcept C2780783641 @default.
• W2785465551 hasConcept C502942594 @default.
• W2785465551 hasConcept C53227056 @default.
• W2785465551 hasConcept C54355233 @default.
• W2785465551 hasConcept C81885089 @default.
• W2785465551 hasConcept C82210918 @default.
• W2785465551 hasConcept C86803240 @default.
• W2785465551 hasConcept C96232424 @default.
• W2785465551 hasConceptScore W2785465551C121608353 @default.
• W2785465551 hasConceptScore W2785465551C153911025 @default.
• W2785465551 hasConceptScore W2785465551C159047783 @default.
• W2785465551 hasConceptScore W2785465551C203233990 @default.
• W2785465551 hasConceptScore W2785465551C2522874641 @default.
• W2785465551 hasConceptScore W2785465551C2777283488 @default.
• W2785465551 hasConceptScore W2785465551C2780783641 @default.
• W2785465551 hasConceptScore W2785465551C502942594 @default.
• W2785465551 hasConceptScore W2785465551C53227056 @default.
• W2785465551 hasConceptScore W2785465551C54355233 @default.
• W2785465551 hasConceptScore W2785465551C81885089 @default.
• W2785465551 hasConceptScore W2785465551C82210918 @default.
• W2785465551 hasConceptScore W2785465551C86803240 @default.
• W2785465551 hasConceptScore W2785465551C96232424 @default.
• W2785465551 hasIssue "1_Supplement" @default.
• W2785465551 hasLocation W27854655511 @default.
• W2785465551 hasOpenAccess W2785465551 @default.
• W2785465551 hasPrimaryLocation W27854655511 @default.
• W2785465551 hasRelatedWork W1973400876 @default.
• W2785465551 hasRelatedWork W2020412555 @default.
• W2785465551 hasRelatedWork W2109415128 @default.
• W2785465551 hasRelatedWork W2374386140 @default.
• W2785465551 hasRelatedWork W2805987454 @default.
• W2785465551 hasRelatedWork W3004774535 @default.
• W2785465551 hasRelatedWork W3030128272 @default.
• W2785465551 hasRelatedWork W3030276183 @default.
• W2785465551 hasRelatedWork W3032242318 @default.
• W2785465551 hasRelatedWork W4300748296 @default.
• W2785465551 hasVolume "17" @default.
• W2785465551 isParatext "false" @default.
• W2785465551 isRetracted "false" @default.
• W2785465551 magId "2785465551" @default.
• W2785465551 workType "article" @default.